HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


GSK: Glaxosmithkline Plc - Stock News Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Company News |  Zacks Commentary
GLAXOSMITHKLINE PLC (NYSE)
GSK 41.53 0.06 (0.14%) Vol.  1,164,239 16.00 CST

Nov 20, 2009 A/H1N1 flu vaccine withdrawn in Canada due to high number of allergic reactions
Nov 20, 2009 Trading Review for Vivus Inc. Issued by Beacon Equity
Nov 19, 2009 Trading Overview for Sinobiopharma Inc. Issued by StockPreacher.com
Nov 19, 2009 Agreement for donation of pandemic H1N1 vaccine signed
Nov 18, 2009 Anti-Smoking Vaccine from Glaxo
Nov 17, 2009 bioMerieux and GSK Sign Theranostics Agreement to Develop Predictive Test for Selecting Breast Cancer Treatment
Nov 17, 2009 Anacor Initiates Phase I Clinical Development for AN3365 -- A Novel Antibiotic for the Treatment of Gram-Negative Infections
Nov 16, 2009 Canada : Health Canada Approves a Canadian Unadjuvanted H1N1 Flu Vaccine
Nov 16, 2009 United States : Glaxo H1N1 Vaccine Approved
Nov 16, 2009 FDA approves additional H1N1 vaccine
Nov 16, 2009 Zacks Analyst Blog Highlights: GlaxoSmithKline plc, Sanofi-Aventis, Novartis, Baxter International and AstraZeneca
Nov 16, 2009 GlaxoSmithKline Up 31.2% Since SmarTrend's Buy Recommendation
Nov 16, 2009 Nabi and GlaxoSmithKline to Develop Anti-Smoking Vaccine
Nov 16, 2009 SFDA approves H1N1 vaccine
Nov 16, 2009 Nabi Biopharmaceuticals to Hold Conference Call
 
ZACKS COMMENTARY FOR GSK
Nov 20, 2009 Zacks Blog: Biogen's Rituxan Label Expansion Delayed
Nov 19, 2009 Zacks Blog: Panel Backing for Prevnar 13
Nov 17, 2009 Zacks Blog: Anti-Smoking Vaccine from Glaxo
Nov 16, 2009 Zacks Blog: Zacks Analyst Blog Highlights: GlaxoSmithKline plc, Sanofi-Aventis, Novartis, Baxter International and AstraZeneca
Nov 13, 2009 Zacks Blog: Glaxo H1N1 Vaccine Approved
Nov 13, 2009 Zacks Blog: Zacks Analyst Blog Highlights: Hewlett Packard Company, 3Com Corporation, Cisco Systems Inc., Wal-Mart Stores Inc. and GlaxoSmithKline, plc
Nov 12, 2009 Zacks Blog: Glaxo Reports Higher Revenues
Nov 11, 2009 Zacks Blog: Cornerstone Tops Zacks Ests
Nov 10, 2009 Industry Outlook: Big Pharma & Biotech
Nov 10, 2009 Zacks Analyst Interviews: Big Pharma & Biotech
Nov 09, 2009 Zacks Blog: Big Pharma and Biotech
Nov 09, 2009 Zacks Blog: Santarus Reports Strong Quarter

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research